MBX Biosciences (MBX) announced the appointment of Mark Soued as chief commercial officer. Most recently, Soued served as senior VP, head of U.S. at Alnylam Pharmaceuticals (ALNY).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- MBX Biosciences initiated with an Outperform at LifeSci Capital
- Options Volatility and Implied Earnings Moves Today, March 23, 2026
- MBX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MBX Biosciences Advances Avail Phase 2 Trial in Hypoparathyroidism: What Investors Should Watch
- MBX Biosciences files automatic mixed securities shelf